Association between <italic style="font-style: italic">Qingfei Paidu Granules </italic>（清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases

GE Youwen; ZHENG Jian; ZONG Xingyu; HE Rong; WANG Lijuan; ZANG Guodong; TIAN Mei; JI Xinyu; GONG Zhaoyuan; GUO Yang; WANG Jingya; SHI Nannan; MA Yan; JIA Xinhua; JIN Aning; WANG Yanping

doi:10.13288/j.11-2166/r.2022.20.010

您当前的位置：

首页 >

文章列表页 >

Association between Qingfei Paidu Granules （清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases

更新时间：2022-10-13

- Association between Qingfei Paidu Granules （清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases
- Journal of Traditional Chinese Medicine Vol. 63, Issue 20, Pages: 1952-1957(2022)
- 作者机构：
  
  1.中国中医科学院中医临床基础医学研究所，北京市东城区东直门内南小街16号，100700
  2.山东中医药大学附属医院
  3.国家中医药管理局中医师资格认证中心
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2022.20.010
  CLC：
- Received：01 August 2022，
  
  Revised：2022-08-24，
  
  Published：17 October 2022
- 稿件说明：
移动端阅览
葛又文,郑建,宗星煜等.新型冠状病毒肺炎奥密克戎变异毒株无症状感染者使用清肺排毒颗粒时间与核酸转阴时间的相关性分析[J].中医杂志,2022,63(20):1952-1957.

GE Youwen,ZHENG Jian,ZONG Xingyu,et al.Association between Qingfei Paidu Granules （清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases[J].Journal of Traditional Chinese Medicine,2022,63(20):1952-1957.
葛又文,郑建,宗星煜等.新型冠状病毒肺炎奥密克戎变异毒株无症状感染者使用清肺排毒颗粒时间与核酸转阴时间的相关性分析[J].中医杂志,2022,63(20):1952-1957. DOI： 10.13288/j.11-2166/r.2022.20.010.

GE Youwen,ZHENG Jian,ZONG Xingyu,et al.Association between Qingfei Paidu Granules （清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases[J].Journal of Traditional Chinese Medicine,2022,63(20):1952-1957. DOI： 10.13288/j.11-2166/r.2022.20.010.

摘要

目的

探讨不同时间开始使用清肺排毒颗粒治疗新型冠状病毒肺炎（简称“新冠肺炎”）奥密克戎变异毒株无症状感染者的疗效。

方法

回顾性收集2022年3月8—24日在山东省青岛市红岛方舱医院收治的服用清肺排毒颗粒的新冠肺炎奥密克戎变异毒株无症状感染者病例资料。根据核酸检测阳性后开始服药时间分为≤3天组、4~6天组、7~9天组、≥10天组，比较各组患者基线资料、核酸转阴时间，采用多元线性回归分析年龄、开始服药不同时间对核酸转阴时间的影响，并记录不良事件发生及转归情况。

结果

共纳入患者111例，其中男性50例，女性61例，年龄中位数35岁，有合并症者12例。≤3天组4例，4~6天组57例，7~9天组42例，≥10天组8例，各组患者年龄、性别及合并症方面比较差异无统计学意义（

＞0.05）。核酸转阴时间：≤3天组为3.0（2.3，3.0）天，4~6天组为7.0（7.0，8.0）天，7~9天组为9.0（8.0，10.0）天，≥10天组为11.0（11.0，12.0）天，各组核酸转阴时间比较差异有统计学意义（

＜0.001）。多元线性回归结果显示，年龄与核酸转阴时间无相关性（

=0.008，

=0.886）；开始服药时间与核酸转阴时间呈正相关，每延迟1天用药，核酸转阴天数增加0.885天（

＜0.001，调整

=0.8）。所有患者在服药期间未出现严重不良事件，无患者转为确诊病例，均痊愈出院。

结论

新冠肺炎奥密克戎变异毒株无症状感染者越早开始服用清肺排毒颗粒治疗，核酸转阴时间越短。

Abstract

Objective

To explore the association between

Qingfei Paidu Granules

（清肺排毒颗粒， QFPDG） initiated at different time points and clinical outcomes in asymptomatic patients infected with Omicron variant of coronavirus disease 2019 （COVID-19）.

Methods

This retrospective study recruited asymptomatic Omicron COVID-19 cases who have been treated by QFPDG from Qingdao Hongdao fangcang shelter hospital from 14th March to 19th March， 2022. Patients were divided into four groups： ≤3 days group， 4-6 days group， 7-9 days group and ≥10 days group. The baseline data and duration of viral shedding were compared between groups， multivariate linear regression was used to analyze the influence of age and treatment initiation time on duration of viral shedding. The adverse events and prognosis of the patients were recorded.

Results

A total of 111 asymptomatic patients were included. Of them， 50 were males and 61 were females， with the median age of 35 years. Twelve patients had comorbidities. There were four cases in the ≤3 days group， 57 cases in the 4-6 days group， 42 cases in the 7-9 days group， and 8 cases in the ≥10 days group， having no significant differences in age， gender and comorbidities at baseline （

＞0.05）. The median duration of viral shedding was 3.0 （2.3， 3.0） days， 7.0 （7.0， 8.0） days， 9.0 （8.0， 10.0） days， and 11.0 （11.0， 12.0） days in the groups of ≤3 days， 4-6 days， 7-9 days and ≥10 days， respectively， with significant difference between groups （

＜0.001）. The multivariate linear regression showed that there was no correlation between age and duration of viral shedding （

= 0.008，

= 0.886）， while the medication initiation time was positively correlated with duration of viral shedding （

＜0.001， adjusted

= 0.8）， suggesting that duration of viral shedding increased by 0.885 days as medication was initiated one day later. No serious adverse events occurred during medication， and none of the patients were converted into confirmed cases and were cured and discharged from hospitals.

Conclusion

Early treatment with QFPDG is linked to a shorter duration of viral shedding in asymptomatic cases infected with Omicron variant of COVID-19.

关键词

Keywords

references

国家中医药管理局 . 世卫组织：中医药能有效治疗新冠肺炎［EB/OL］.（ 2022-04-06 ）［ 2022-05-20 ］. http：//www.satcm.gov.cn/xinxifabu/shipinxinwen/2022-04-06/25807.html http://www.satcm.gov.cn/xinxifabu/shipinxinwen/2022-04-06/25807.html .

XIN S ， CHENG X ， ZHU B ， et al . Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with western medicine for COVID-19 treatment ［J］. Biomed Pharmacother ， 2020 ， 129 ： 110500 . doi： 10.1016/j.biopha.2020.110500 http://dx.doi.org/10.1016/j.biopha.2020.110500

ZHANG L ， ZHENG X ， BAI X ， et al . Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19： a national retrospective registry study ［J］. Phytomedicine ， 2021 ， 85 ： 153531 . doi： 10.1016/j.phymed.2021.153531 http://dx.doi.org/10.1016/j.phymed.2021.153531 .

王晶亚，李慧珍，郭玉娜，等 . 清肺排毒汤联合西医常规疗法治疗老年新型冠状病毒肺炎157例临床疗效回顾性研究［J］. 中医杂志， 2021 ， 62 （ 20 ）： 1788 - 1794 .

焦丽雯，郭玉娜，宗星煜，等 . 清肺排毒汤联合西医常规疗法治疗新型冠状病毒肺炎合并2型糖尿病患者49例回顾性临床研究［J］. 中医杂志， 2021 ， 62 （ 19 ）： 1709 - 1714 .

李慧珍，王晶亚，郭玉娜，等 . 清肺排毒汤联合西医常规疗法治疗新型冠状病毒肺炎合并高血压病119例临床疗效回顾性分析［J］. 中医杂志， 2021 ， 62 （ 20 ）： 1795 - 1800 .

ZONG X ， LIANG N ， WANG J ， et al . Treatment effect of Qingfei Paidu decoction combined with conventional treatment on COVID-19 patients and other respiratory diseases： a multi-center retrospective case series ［J］. Front Pharmacol ， 2022 ， 13 ： 849598 . doi： 10.3389/fphar.2022.849598 http://dx.doi.org/10.3389/fphar.2022.849598 .

ZHANG L ， MA Y ， SHI N ， et al . Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19： a systematic review and meta-analysis ［J］. Phytomedicine ， 2022 ， 102 ： 154166 . doi： 10.1016/j.phymed.2022.154166 http://dx.doi.org/10.1016/j.phymed.2022.154166 .

LIU SH ， MA Y ， SHI NN ， et al . Qingfei Paidu decoction for COVID-19： a bibliometric analysis ［J］. Biomed Environ Sci ， 2021 ， 34 （ 9 ）： 755 - 760 .

SHI N ， LIU B ， LIANG N ， et al . Association between early treatment with Qingfei Paidu decoction and favo-rable clinical outcomes in patients with COVID-19： a retrospective multicenter cohort study ［J］. Pharmacol Res ， 2020 ， 161 ： 105290 . doi： 10.1016/j.phrs. 2020. 105290 http://dx.doi.org/10.1016/j.phrs.2020.105290 .

国家药品监督管理局 . 国家药监局批准清肺排毒颗粒、化湿败毒颗粒、宣肺败毒颗粒上市［EB/OL］.（ 2021-03-02 ）［ 2022-03-02 ］. https：//www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20210302190503177.html https://www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20210302190503177.html .

World Health Organization . Enhancing readiness for Omicron（B . 1 . 1 . 529 ）： technical brief and priority actions for member states ［R/OL］. Geneva ： WHO .（ 2021-12-23 ）［ 2022-06-22 ］. https：//www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf https://www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf .

NEALON J ， COWLING BJ . Omicron severity： milder but not mild ［J］. Lancet ， 2022 ， 399 （ 10323 ）： 412 - 413 .

VIANA R ， MOYO S ， AMOAKO DG ， et al . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa ［J］. Nature ， 2022 ， 603 （ 7902 ）： 679 - 686 .

国务院应对新型冠状病毒肺炎疫情联防联控机制综合组 . 关于印发新型冠状病毒肺炎防控方案（第八版）的通知［EB/OL］.（ 2021-05-14 ）［ 2022-06-22 ］. http：//www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml http://www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml .

国家卫生健康委办公厅，国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案（试行第八版）的通知［EB/OL］.（ 2020-08-19 ）［ 2022-06-22 ］. http：//www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml http://www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml .

WANG Y ， ZHANG D ， DU G ， et al . Remdesivir in adults with severe COVID-19： a randomised， double-blind， placebo-controlled， multicentre trial ［J］. Lancet ， 2020 ， 395 （ 10236 ）： 1569 - 1578 .

BEIGEL JH ， TOMASHEK KM ， DODD LE . Remdesivir for the treatment of Covid-19： preliminary report. Reply ［J］. N Engl J Med ， 2020 ， 383 （ 10 ）： 994 .

南岩东，王娟，姜华，等 . 方舱医院收治无症状与轻型新型冠状病毒感染者临床特征分析［J］. 医学争鸣， 2022 ， 13 （ 1 ）： 8 - 11 .

HUNG IF ， LUNG KC ， TSO EY ， et al . Triple combination of interferon beta-1b， lopinavir-ritonavir， and ribavirin in the treatment of patients admitted to hospital with COVID-19： an open-label， randomised， phase 2 trial ［J］. Lancet ， 2020 ， 395 （ 10238 ）： 1695 - 1704 .

REN W ， MA Y ， WANG R ， et al . Research advance on Qingfei Paidu decoction in prescription principle， mechanism analysis and clinical application ［J］. Front Pharmacol ， 2020 ， 11589714 . doi： 10.3389/fphar. 2020. 589714 http://dx.doi.org/10.3389/fphar.2020.589714 .

WANG Q ， ZHU H ， LI M ， et al . Efficacy and safety of Qingfei Paidu decoction for treating COVID-19： a syste-matic review and meta-analysis ［J］. Front Pharmacol ， 2021 ， 12 ： 688857 . doi： 10.3389/fphar.2021.688857 http://dx.doi.org/10.3389/fphar.2021.688857 .

王芳，郭旸，焦丽雯，等 . 清肺排毒汤联合西医常规治疗重型新型冠状病毒肺炎50例临床疗效回顾性分析［J］. 中医杂志， 2021 ， 62 （ 20 ）： 1801 - 1805 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Analysis of Yangfei Tongluo Formula（养肺通络方）in the Adjuvant Treatment of Post-COVID-19 Pulmonary Fibrosis

Promoting Establishment of a Collaboration and Sharing Mechanism on Clinical Trials: Strategic Thinking During Epidemic Spread Period

An Analyze of The Traditional Chinese Medicine Prevention and Treatment Interventions For COVID-19

试析从寒疫论治新型冠状病毒肺炎

Efficacy and Economic Evaluation of Weishi Qingjin Formula （苇石清金方）in the Treatment of Adult Community-Acquired Pneumonia with Phlegm-Heat Obstructing the Lung Syndrome：A Multicenter Retrospective Real-World Cohort Study

Related Author

ZHANG Yong

JIANG Zihan

HUANG Hesong

LIU Lin

YANG Wenchao

YU Qiao

WU Wei

XIAO Jingjing

Related Institution

PLA General Hospital of Central Theatre Command

Wuhan University of Science and Technology

Dongzhimen Hospital,Beijing University of Chinese Medicine

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine

Institute of Basic research in Clinical Medicine,China Academy of Chinese Medical Sciences

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Association between Qingfei Paidu Granules （清肺排毒颗粒） Initiated at Different Timepoints and Clinical Outcomes in Asymptomatic COVID-19 Omicron Infection Cases

DOI：10.13288/j.11-2166/r.2022.20.010

摘要

Abstract

关键词

Keywords

references